ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc.
Your view on ZIVO
Overview
What the company does, where it operates, and who runs it.
About ZIVO Bioscience, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Bernard Payne
- Headquarters
- 21 East Long Lake Road, Bloomfield Hills, MI, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Bernard Payne
- Headquarters
- 21 East Long Lake Road, Bloomfield Hills, MI, US
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ZIVO Bioscience, Inc., and the rating behind it. ZIVO last traded at $9.36; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ZIVO Bioscience, Inc.. Starting points for ZIVO Bioscience, Inc.: EPS -$1.33, beta 0.22 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ZIVO Bioscience, Inc.. ZIVO Bioscience, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ZIVO Bioscience, Inc.. Trailing twelve-month EPS for ZIVO Bioscience, Inc. stands at -$1.33. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ZIVO Bioscience, Inc.. ZIVO Bioscience, Inc. has reported as a listed company since 2003. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ZIVO Bioscience, Inc. valued side by side against its closest peers. ZIVO Bioscience, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ZIVO Bioscience, Inc., and how their positions are changing. At a $36.4M market value, institutional positions materially move ZIVO Bioscience, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ZIVO Bioscience, Inc. executives and directors. Shares of ZIVO Bioscience, Inc. have traded between $6.95 and $21.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ZIVO Bioscience, Inc.. ZIVO Bioscience, Inc. is a $36.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ZIVO Bioscience, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ZIVO Bioscience, Inc.. Coverage tracks ZIVO Bioscience, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.